Femasys inc. expands fembloc pivotal trial enrollment securing first academic site to participate

Atlanta, sept. 27, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it has activated enrollment for its pivotal fembloc trial at its first academic site located in brooklyn, new york. the fembloc intratubal occlusion for transcervical permanent birth control (the “finale” trial) is being conducted to investigate the safety and efficacy of its investigational permanent birth control candidate, fembloc®. the fda approved multi-center pivotal trial is designed to address the high unmet need that exists for women seeking permanent birth control for whom elective surgery remains the only option.
FEMY Ratings Summary
FEMY Quant Ranking